Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. – UroToday
|
Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
UroToday The responsiveness of bladder cancer to immunotherapy was first established in nonmuscle invasive disease in 1976 with intravesical instillations of bacillus Calmette-Guérin (BCG). Very recently immune checkpoint inhibitors demonstrated good activity … |
pulse |
Korea’s first gene therapy Invossa cleared to be sold in Korea …
pulse South Korea’s Kolon Life Science said on Wednesday the Ministry of Food and Drug Safety has granted marketing approval to its new gene therapy to treat … Korea OKs first cell gene therapy ‘Invossa’The Korea Herald Ministry approves 1st domestic gene therapy product – Korea …Korea Biomedical Review S. Korea approves 1st gene therapy drug – Yonhap News AgencyYonhap News |
The Korea Herald |
Korea OKs first cell gene therapy ‘Invossa’
The Korea Herald Korea’s Ministry of Food and Drug Safety has granted approval to Invossa-K Inj., an injectable cell gene therapy for osteoarthritis, a joint disease common among the elderly in which the cartilage that cushions the ends of bones between joints breaks down. |
TheStreet.com |
Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday
TheStreet.com The Oncologic Drugs Advisory Committee will examine the safety of CAR T-cell treatments, an immunotherapy manufactured by Novartis AG (NVS) for treatment of children and young adult leukemia patients who have not responded to traditional treatments. Novartis readies for FDA review of $1 billion CAR-T child cancer hopeReuters UK Novartis dodged deaths from its CAR-T Therapy, but FDA still has safety concernsLabiotech.eu (blog) Novartis’ CAR-T Therapy for Pediatric Leukemia to Face FDA Advisory PanelAJMC.com Managed Markets Network |
Korea Biomedical Review |
Ministry approves 1st domestic gene therapy product
Korea Biomedical Review The Ministry of Food and Drug Safety said Wednesday it granted approval to Kolon’s gene therapy for knee osteoarthritis as the 29th domestically produced drug to gain approval and as the first of its kind. |